Trace Biosciences is creating imaging agents for surgery. Our mission is to revolutionize surgery by highlighting detailed anatomy in real-time. Our first product is a nerve targeting imaging agent that will prevent surgical nerve damage. Nerve injury is a feared surgical complication affecting 25 million patients annually and incurring undue pain, loss of function, and high cost for follow on treatment and pain management. Currently, surgeons are entirely unassisted in nerve identification and preservation, relying solely on naked eye visualization or anatomical knowledge. If we can successfully develop this, our imaging agents will be used in almost all operating theaters, enable true precision surgery, and vastly improve patient outcomes. We are well funded through non-dilutive grants (SBIR, STTR + regional government) as well as venture capital investments. Founded in 2019 we are now developing our first products that will enter clinical trials in 2023.
